lyophilization comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility | Soluble in water | Consistent with peptide nature |
| Typical storage | 2 to 8 degrees Celsius | Refrigerated, dry, protected from light |
| Common analytical method | Reversed-phase HPLC | Purity and impurity profiling |
| Identity confirmation | Mass spectrometry | Molecular mass verification |
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
People with MASLD often have no noticeable symptoms, and it is often only detected during routine blood tests or unrelated abdominal imaging or liver biopsy. In some cases, it can cause symptoms related to liver dysfunction such as fatigue, malaise, and dull right-upper-quadrant abdominal discomfort. Mild yellow discoloration of the skin may occur, although this is rare. MASH can severely impair liver function, leading to cirrhosis, liver failure, and liver cancer.
Thiotepa, as well as its more reactive metabolite, tepa, work as an alkylating agent via its aziridine ring. Due to the basic nature of aziridine and the physiological pH, aziridine is protonated to form the aziridinium ion, resulting in an electrophilic moiety that is highly susceptible to nucleophiles. DNA reacts through the nucleophilic N-7 position of guanine onto the electrophilic aziridine ring, rendering alkylated nucleobases. Thiotepa contains three reactive aziridine rings, allowing a single molecule to alkylate multiple nucleobases. Hence, it is a polyfunctional alkylating agent. This property also gives rise to its ability to cross-link DNA strands. Apart from its mechanism of action, it is suggested that thiotepa can function as a prodrug. Due to its moderate lipophilicity, it first penetrates the cell membrane, followed by hydrolysis to release the more hydrophilic aziridine ring. The aziridine ring can once again alkylate the DNA. The highly reactive metabolite tepa can be considered as an active metabolite and alkylates DNA similar to its parent drug. Ultimately, the alkylation of DNA leads to cell damage and can lead to cell death. Cross-linking blocks the separation of DNA strands, inhibiting replication and the proliferation of cells.
== Regulatory history == The device was evaluated under an investigational device exemption in the United States, where it was compared against transforaminal lumbar interbody fusion. It was later granted FDA Breakthrough Device designation in 2021, followed by full FDA approval in 2023 after demonstrating superiority over fusion in composite clinical success. The TOPS System also holds CE marking, signifying that it meets health, safety, and environmental requirements for sale in the European Economic Area.
== Recovery == A majority of patients generally report feeling minimal discomfort after Mohs surgery, with the most discomfort being reported the day of surgery and the day after. After the first two days, the pain steadily reduces over the next week. The surgery is overall well-tolerated and has a fast recovery. Many patients don’t require analgesics or pain medication, but of those who do, acetaminophen is usually enough to manage pain. Only a few go on to need a prescription pain medication. When multiple areas are operated on at once or when the scalp is involved, pain tends to be increased.
Sources: en.wikipedia.org
The One Big Beautiful Bill Act (OBBBA) is a key part of the Trump administration's economic agenda. It permanently extends the individual tax rates Trump signed into law in 2017, which were set to expire at the end of 2025. It raises the cap on the state and local tax deduction to $40,000 for taxpayers making less than $500,000, with the cap reverting to $10,000 after five years. It includes several tax deductions for tips, overtime pay, auto loans, and creates Trump accounts, allowing parents to create tax-deferred accounts for the benefit of their children, all set to expire in 2028. It includes a permanent $200 increase in the child tax credit, a 1% tax on remittances, and a tax hike on investment income from college endowments. It phases out some clean energy tax credits that were included in the Biden-era Inflation Reduction Act, and promotes fossil fuels over renewable energy. It increases a tax credit for advanced semiconductor manufacturing and repeals a tax on silencers. The OBBBA has been criticized for limiting health insurance coverage and resulting in an upwards transfer of wealth. It is expected to add a total of $3 trillion to the national debt of the United States by 2034, according to the Congressional Budget Office.
=== Cardiac arrest === While intravenous calcium has been used in cardiac arrest, its general use is not recommended. Cases of cardiac arrest in which it is still recommended include high blood potassium, low blood calcium such as may occur following blood transfusions, and calcium channel blocker overdose. There is the potential that general use could worsen outcomes. If calcium is used, calcium chloride is generally the recommended form.
The system was deliberately developed using existing commercially available technology to speed introduction. The development team could not afford the time to develop and debug new technology. Watt, a pragmatic engineer, believed "third-best" would do if "second-best" would not be available in time and "best" never available at all. This led to the use of the 50 m wavelength (around 6 MHz), which Wilkins suggested would resonate in a bomber's wings and improve the signal. Unfortunately, this also meant that the system was increasingly blanketed by noise as new commercial broadcasts began taking up this formerly high-frequency spectrum. The team responded by reducing their own wavelength to 26 m (around 11 MHz) to get clear spectrum. To everyone's delight, and contrary to Wilkins' 1935 calculations, the shorter wavelength produced no loss of performance. This led to a further reduction to 13 m, and finally the ability to tune between 10 and 13 m, (roughly 30-20 MHz) to provide some frequency agility to help avoid jamming. Wilkins' method of height-finding was added in 1937. He had originally developed this system as a way to measure the vertical angle of transatlantic broadcasts while working at the RRS. The system consisted of several parallel dipoles separated vertically on the receiver masts. Normally the RDF goniometer was connected to two crossed dipoles at the same height and used to determine the bearing to a target return.
Sources: en.wikipedia.org
There are three types of muscles—cardiac, skeletal, and smooth. Smooth muscles are used to control the flow of substances within the lumens of hollow organs, and are not consciously controlled. Skeletal and cardiac muscles have striations that are visible under a microscope due to the components within their cells. Only skeletal and smooth muscles are part of the musculoskeletal system and only the muscles can move the body. Cardiac muscles are found in the heart and are used only to circulate blood; like the smooth muscles, these muscles are not under conscious control. Skeletal muscles are attached to bones and arranged in opposing groups around joints. Muscles are innervated, whereby nervous signals are communicated by nerves, which conduct electrical currents from the central nervous system and cause the muscles to contract.
== Further reading == Andrew H. Cutler, Metallurgical Properties of Lunar and Asteroidal Steels, 7th Princeton/AIAA/SSI Conference, 1985. David Gump, Space Enterprise: Beyond NASA, Praeger Publishers, 1990, ISBN 0-275-93314-8. T. A. Heppenheimer, Colonies in Space, 1977, Stackpole Books, ISBN 0-8117-0397-5. Lewis, J., Matthews, M.S., and Guerrieri, M.L., Editors, 1993, Resources of Near-Earth Space, University of Arizona Press, 1993. ISBN 978-0-8165-1404-5. Wahl, Bruno W. (1968). Analysis of Selected Opportunities for Manufacturing in Space. McDonald Douglas Astronautics Company.
=== List of superintendents === Shawn Joseph (interim 2025–2026; 2026-present) Millard House II (2023–2025) Monica Goldson, CEO (interim 2018–2019; 2019–2023) Kevin M. Maxwell, CEO (2013–2018) Alvin Crawley (interim 2012–2013) William R. Hite, Jr. (interim 2008–2009; 2009–2012) John E. Deasy (2006–2008) Howard A. Burnett (interim 2005–2006) André J. Hornsby (2003–2005) Iris T. Metts (1999–2003) Jerome Clark (1995–1999) Edward M. Felegy (1991–1995) John A. Murphy (1984–1991) Edward J. Feeney (1976–1984) Carl W. Hassel (1970–1976) William S. Schmidt (1951–1970) G. Gardner Shugart (1944–1951) Nicholas Orem Sr. (1921–1943) E.S. Burroughs (1915–1921) Frederick Sasscer Jr. (1902–1914)
Sources: en.wikipedia.org
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.
Reversed-phase high-performance liquid chromatography is commonly used to separate and quantify the peptide and its impurities. Mass spectrometry is often paired with it to confirm identity. Together they provide a profile of related substances.
Extreme pH values accelerate hydrolytic degradation of the peptide backbone. Buffered solutions in a near-neutral range generally slow this process. Solution age and temperature also affect the rate of breakdown.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the standard technique for purity and content. Mass spectrometry provides orthogonal confirmation of identity. The two are normally used together rather than in isolation.